CLINUVEL publicly files 20-F to U.S. SEC
Open PDF
| Stock | Clinuvel Pharmaceuticals Ltd (CUV.ASX) |
|---|---|
| Release Time | 16 Jun 2026, 9:06 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Clinuvel Files 20-F with SEC for Nasdaq Listing
Key Points
- Clinuvel files Form 20-F with U.S. SEC
- Aims to list American Depository Shares (ADS) on Nasdaq
- Upgrade from ADR Level I to Level II
- No capital raise or new share issuance planned
Full Summary
Clinuvel Pharmaceuticals Ltd has filed a Form 20-F Registration Statement with the U.S. Securities and Exchange Commission (SEC), aiming to list American Depository Shares (ADS) on the Nasdaq Stock Market. This upgrade from its current American Depository Receipt (ADR) Level I program to Level II reflects increased investor interest in the company's vitiligo development program. The ADS is expected to trade on Nasdaq with the ticker CUVL. Clinuvel does not plan to raise capital or issue new shares as a result of this upgrade.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In